ARTICLE | Company News
Actelion sales and marketing update
December 10, 2001 8:00 AM UTC
ATLN launched its Tracleer bosentan oral endothelin receptor antagonist to treat pulmonary arterial hypertension (PAH) in the U.S. Genentech Inc. (DNA, South San Francisco, Calif.) has U.S. co-promo...